

1 **Development of Fluorogenic Substrates of**
2 **α -L-Fucosidase Useful for Inhibitor Screening and**
3 **Gene-expression Profiling**
4

5 *Kazuki Miura, Takumi Tsukagoshi, Takako Hirano, Toshiyuki Nishio, Wataru*
6 *Hakamata**

7
8 Department of Chemistry and Life Science, College of Bioresource Sciences, Nihon
9 University, 1866 Kameino, Fujisawa-shi, Kanagawa 252-0880, Japan

10
11
12 **Supporting Information**
13

14 *Abbreviations*

15
16 *General Information for Substrates Synthesis*

17
18 *Photochemical Characterization of Substrates*

19
20 *Computational analysis*

21
22 *General Information for Cell-based Assays*

23
24 *General Information for in vitro Assays*

25
26 *Gene expression profiling by DNA microarray*

27
28 *Additional References*
29

1 **Abbreviations:** 2MeTG, 2-methyl TokyoGreen; ADDP,
2 1,1'-(azodicarbonyl)dipiperidine; AF, area of fluorescence; AV, average value; COSY,
3 correlation spectroscopy; CV, coefficient of variation; DFJ, deoxyfuconojirimycin;
4 DMSO, dimethyl sulfoxide; AcOEt, ethyl acetate; ESI, electrospray ionization; HMQC,
5 heteronuclear multiple quantum correlation; MS, mass spectrometry; NMR, nuclear
6 magnetic resonance; PBS, phosphate-buffered saline (not including Ca²⁺ and Mg²⁺); RT,
7 room temperature; SD, standard deviation; TBP, tributylphosphine; tFuc, tissue
8 α -L-fucosidase; TFMU, 4-trifluoromethylumbelliferone; THF; tetrahydrofuran

9
10 **General information for substrate synthesis:** New compounds were characterized by
11 ¹H-NMR, ¹³C-NMR, ¹H-¹H COSY, and HMQC spectrometry; mass spectrometry (MS);
12 and elemental analysis. The nuclear magnetic resonance (NMR) spectra were recorded
13 with a JEOL ECA500 spectrometer (JEOL, Tokyo, Japan; 500 MHz for ¹H and 125 MHz
14 for ¹³C). Chemical shifts were expressed in ppm as downfield shifts from Me₄Si.
15 Low-resolution mass spectra were obtained with a Waters Quattro Premier XE
16 instrument (Waters, Milford, MA, USA) under positive and negative ion electrospray
17 ionization (ESI) conditions. Column chromatography was performed using a Silica Gel
18 60N (Kanto Chemical, Tokyo, Japan; spherical neutral particle size: 100–210 μ m). The
19 progress of all reactions was monitored by thin-layer chromatography using a Silica Gel
20 60 F₂₅₄ (0.25 mm; Merck Millipore, Billerica, MA, USA).

21
22 *Synthesis of 1,2,3,4-tetra-O-acetyl-L-fucopyranose (7):* L-Fucose (5.00 g; 30.5 mmol)
23 was dissolved in 70 mL pyridine, followed by the addition of acetic anhydride (17.3 mL;
24 183 mmol). After stirring at room temperature (RT) for 24 h, the reaction mixture was
25 poured into ethyl acetate (AcOEt). The organic layer was then washed with 1 M HCl,
26 saturated NaHCO₃ (aq), and saturated NaCl (aq) and dried over Na₂SO₄. The obtained
27 residue was purified by column chromatography on silica gel (2:1, hexane:AcOEt) to
28 obtain 9.90 g (98% yield) of compound 7. ESI-MS (positive mode): $m/z = 355$ [M +
29 Na]⁺.

1
2 *Synthesis of 2,3,4-tri-O-acetyl-L-fucopyranose (8)*: Compound **7** (1.76 g; 5.29 mmol)
3 was dissolved in 10 mL of a mixed solution (100:1, 1,2-dimethoxyethane:H₂O), followed
4 by the addition of ammonium carbonate (4.80 g; 47.7 mmol). After stirring at RT for 7
5 days, the reaction mixture was filtered and concentrated *in vacuo*. The obtained residue
6 was purified by column chromatography on silica gel (1:1, hexane:AcOEt) to obtain 1.01
7 g (66% yield) of compound **8**. ESI-MS (positive mode): $m/z = 313 [M + Na]^+$.

8
9 *Synthesis of 2,3,4-tri-O-acetyl-L-fucopyranosyl 2,2,2-trichloroacetimidate (9)*:
10 Compound **8** (3.68 g; 12.7 mmol) was dissolved in dry 20 mL CH₂Cl₂, followed by the
11 addition of 1,8-diazabicyclo[5.4.0]-7-undecene (380 μ L; 2.53 mmol) and
12 trichloroacetonitrile (3.80 mL; 38.0 mmol). After stirring at RT for 30 min under N₂
13 atmosphere, the mixture was poured into AcOEt. The organic layer was then washed
14 with H₂O and saturated NaCl (aq) and dried over Na₂SO₄. The obtained residue was
15 purified by column chromatography on silica gel (1:1, hexane:AcOEt) to obtain 4.92 g
16 (89% yield) of compound **9**, which was immediately used for the next step as it may
17 decompose when handled and stored.

18
19 *Synthesis of 4-(((tert-butyldimethylsilyloxy)methyl)phenyl*
20 *2,3,4-tri-O-acetyl- α -L-fucopyranoside (10)*: Compound **9** (1.39 g; 3.21 mmol) was
21 dissolved in dry 30 mL CH₂Cl₂, followed by the addition of
22 4-(((tert-butyldimethylsilyloxy)methyl)phenol (1.15 g; 4.81 mmol; [1]) and boron
23 trifluoride ethyl ether complex (205 μ L; 1.60 mmol). After stirring at -40 °C for 10 min
24 under N₂ atmosphere, the reaction mixture was poured into AcOEt. The organic layer
25 was then washed with saturated NaHCO₃ (aq) and saturated NaCl (aq) and then dried
26 over Na₂SO₄. The obtained residue was purified by flush column chromatography on
27 silica gel (2:1, hexane:AcOEt) to obtain 1.56 g (95% yield) of compound **10**, which was
28 immediately used for the next step as it may decompose when handled and stored.
29 ESI-MS (positive mode): $m/z = 533 [M + Na]^+$.

1
2 *Synthesis of 4-(hydroxymethyl)phenyl 2,3,4-tri-O-acetyl- α -L-fucopyranoside (11):*
3 Compound **10** (0.40 g; 0.79 mmol) was dissolved in 5 mL CH₃OH, followed by the
4 addition of 0.15 g DOWEX 50W-X8 (H⁺ form). After stirring at RT for 4.5 h, the
5 reaction mixture was filtered and concentrated *in vacuo*. The obtained residue was
6 purified by column chromatography on silica gel (3:5, hexane:AcOEt) to obtain 0.29 g
7 (92% yield) of compound **11**. Characterization of compound **11** by ¹H-NMR, ¹³C-NMR,
8 and MS agreed with previously reported data [2]. ¹H-NMR (500 MHz, CDCl₃): δ 1.28 (d,
9 3H, J_{5-6} =6.3 Hz, H-6), 2.02 (s, 3H, -CH₃, Ac), 2.06 (s, 3H, -CH₃, Ac), 2.21 (s, 3H, -CH₃,
10 Ac), 3.96 (qd, 1H, H-5), 4.65 (d, 2H, J =5.2 Hz, benzyl position), 5.04 (d, 1H, J =8.0 Hz),
11 5.11 (dd, 1H, J =3.5 Hz and 10.9 Hz), 5.31 (d, 1H, J =8.0 Hz), 5.47 (dd, 1H, J =8.0 Hz and
12 10.3 Hz), 7.00 (d, 1H, J =8.6 Hz), 7.31 (d, 1H, J =8.6 Hz). ¹³C-NMR (125 MHz, CDCl₃):
13 δ 16.17 (C6), 20.67 (-CH₃, Ac), 20.73 (-CH₃, Ac), 20.79 (-CH₃, Ac), 64.87, 68.71, 69.52,
14 69.99, 71.20, 99.58 (C1), 116.95, 128.52, 135.60, 156.68, 169.53 (-C=O, Ac), 170.27
15 (-C=O, Ac), 170.72 (-C=O, Ac). ESI-MS (positive mode): m/z = 419 [M + Na]⁺.

16
17 *Synthesis of substrate 1:* Compound **11** (0.11 g; 0.28 mmol) was dissolved in 100 mL dry
18 tetrahydrofuran (THF), followed by the addition of 1,1'-(azodicarbonyl)dipiperidine
19 (ADDP; Tokyo Chemical Industry, Tokyo, Japan; A1051; 0.43 g; 1.66 mmol),
20 tributylphosphine (TBP; Tokyo Chemical Industry; T0361; 410 μ L; 1.66 mmol), and
21 resorufin (Sigma-Aldrich, St. Louis, MO, USA; 424455; 73.0 mg; 0.33 mmol). After
22 stirring at 40 °C for 2.5 h under N₂ atmosphere, the reaction mixture was poured into
23 AcOEt. The organic layer was then washed with H₂O, and saturated NaCl (aq) and then
24 dried over Na₂SO₄. The obtained residue was purified twice by column chromatography
25 on silica gel (20:1, CH₂Cl₂:CH₃OH) to obtain 0.14 g (87% yield) of substrate **1**. ¹H-NMR
26 (500 MHz, CDCl₃): δ 1.28 (d, 3H, J_{5-6} =6.0 Hz, H-6), 2.02 (s, 3H, -CH₃, Ac), 2.06 (s, 3H,
27 -CH₃, Ac), 2.21 (s, 3H, -CH₃, Ac), 3.97 (qd, 1H, H-5), 5.07 (d, 1H, J_{1-2} =8.0 Hz, H-1),
28 5.10-5.13 (m, 3H, H-3 and benzyl position), 5.31 (d, 1H, J_{3-4} = J_{4-5} =3.5 Hz, H-4), 5.48
29 (dd, 1H, J_{1-2} = 7.3 Hz, J_{2-3} =10.8 Hz, H-2), 6.32 (d, 1H, J =2.5 Hz), 6.84 (dd, 1H, J =2.5 Hz

1 and 9.8 Hz), 6.87 (d, 1H, $J=2.0$ Hz), 6.99 (dd, 1H, $J=2.5$ Hz and 9.0 Hz), 7.05 (d, 2H, $J=$
2 $=8.5$ Hz), 7.38 (d, 2H, $J=9.0$ Hz), 7.42 (d, 1H, $J=10.0$ Hz), 7.71 (d, 1H, $J=9.5$ Hz).
3 ^{13}C -NMR (125 MHz, CDCl_3): δ 16.17 (C6), 20.63 ($-\underline{\text{C}}\text{H}_3$, Ac), 20.69 ($-\underline{\text{C}}\text{H}_3$, Ac), 20.77
4 ($-\underline{\text{C}}\text{H}_3$, Ac), 68.71 (C2), 69.63 (C5), 69.98 (C4), 70.47 (benzyl position), 71.18 (C3),
5 99.37 (C1), 101.05, 106.79, 114.21, 117.11, 128.51, 129.24, 129.95, 131.62, 134.30,
6 134.71, 145.61, 145.77, 149.80, 157.27, 162.57, 169.46 ($-\underline{\text{C}}=\text{O}$, Ac), 170.21 ($-\underline{\text{C}}=\text{O}$, Ac),
7 170.64 ($-\underline{\text{C}}=\text{O}$, Ac), 186.30 ($-\underline{\text{C}}=\text{O}$, resorufin). ESI-MS (positive mode): $m/z = 614$ [$\text{M} +$
8 Na] $^+$, (negative mode): $m/z = 590$ [$\text{M} - \text{H}$] $^-$. Elemental analysis: Calculated for
9 $\text{C}_{31}\text{H}_{29}\text{NO}_{11}$: C, 62.94; H, 4.94; N, 2.37. Found: C, 62.96; H, 4.94; N, 2.33.

10

11 *Synthesis of substrate 4*: Substrate **1** (0.10 g; 0.18 mmol) was dissolved in 60 mL of
12 mixed solution (5:1, $\text{CH}_3\text{OH}:\text{CH}_2\text{Cl}_2$), followed by the addition of 28% NaOCH_3 in
13 CH_3OH (95 μL). After stirring at 0 $^\circ\text{C}$ for 17 h, the reaction mixture was poured into
14 H_2O and extracted three times with AcOEt . The organic layer was then washed with
15 saturated NaCl (aq) and dried over Na_2SO_4 . The obtained residue was purified by column
16 chromatography on silica gel (8:1, $\text{CH}_2\text{Cl}_2:\text{CH}_3\text{OH}$) to obtain 72.0 mg (88% yield) of
17 substrate **4**. ^1H -NMR (500 MHz, $\text{DMSO}-d_6$): δ 1.11 (d, 3H, $J_{5,6}=6.5$ Hz, H-6), 3.44-3.57
18 (m, 3H, H-2, H-3, and H-4), 3.74 (qd, 1H, H-5), 4.57 (d, 1H, $-\text{OH}$), 4.83-4.84 (m, 2H,
19 $J_{1,2}=8.0$ Hz, H-1 and $-\text{OH}$), 5.16 (d, 1H, $-\text{OH}$), 5.19 (s, 1H benzyl position), 6.26 (d, 1H,
20 $J=2.0$ Hz), 6.77 (dd, 1H, $J=1.8$ Hz and 9.8 Hz), 7.02 (d, 2H, $J=9.0$ Hz), 7.10 (dd, 1H,
21 $J=2.5$ Hz and 9.0 Hz), 7.18 (d, 1H, $J=3.0$ Hz), 7.41 (d, 2H, $J=8.5$ Hz), 7.52 (d, 1H, $J=9.5$
22 Hz), 7.76 (d, 1H, $J=9.0$ Hz). ^{13}C -NMR (125 MHz, $\text{DMSO}-d_6$): δ 16.68 (C6), 69.93,
23 70.12 (benzyl position), 70.32 (C5), 71.00, 73.45, 100.47 (C1), 101.21, 105.70, 114.50,
24 116.19, 128.02, 129.02, 129.79, 131.41, 133.79, 135.01, 145.24, 145.32, 149.84, 157.46,
25 162.46, 185.47 ($-\underline{\text{C}}=\text{O}$, resorufin). ESI-MS (positive mode): $m/z = 488$ [$\text{M} + \text{Na}$] $^+$.
26 Elemental analysis: Calculated for $\text{C}_{25}\text{H}_{23}\text{NO}_8 \cdot 1/2\text{H}_2\text{O}$: C, 63.29; H, 5.10; N, 2.95.
27 Found: C, 62.96; H, 5.31; N, 2.69.

28

29 *Synthesis of substrate 2*: Compound **11** (0.11 g; 0.28 mmol) was dissolved in 20 mL dry

1 THF, followed by the addition of ADDP (0.42 g; 1.67 mmol), TBP (420 μ L; 1.67 mmol),
2 and 4-trifluoromethylumbelliferone (TFMU; Santa Cruz Biotechnology, Dallas, TX,
3 USA; sc-210622A; 80.0 g; 0.33 mmol). After stirring at 40 $^{\circ}$ C for 20 min under N_2
4 atmosphere, the reaction mixture was poured into AcOEt. The organic layer was then
5 washed with saturated $NaHCO_3$ (aq) and saturated NaCl (aq) and then dried over
6 Na_2SO_4 . The obtained residue was purified by column chromatography on silica gel (1:1,
7 hexane:AcOEt) to obtain 0.16 g (94% yield) of substrate **2**. 1H -NMR (500 MHz, $CDCl_3$):
8 δ 1.29 (d, 3H, $J_{5-6}=6.5$ Hz, H-6), 2.02 (s, 3H, $-CH_3$, Ac), 2.06 (s, 3H, $-CH_3$, Ac), 2.21 (s,
9 3H, $-CH_3$, Ac), 3.98 (qd, 1H, H-5), 5.06 (d, 1H, $J_{1-2}=8.0$ Hz, H-1), 5.09-5.13 (m, 3H, H-3
10 and benzyl position), 5.31 (d, 1H, $J_{3-4}=J_{4-5}=3.5$ Hz, H-4), 5.48 (dd, 1H, $J_{1-2}=8.0$ Hz,
11 $J_{2-3}=10.0$ Hz, H-2), 6.63 (s, 1H), 6.93 (d, 1H, $J=3.0$ Hz), 6.98 (dd, 1H, $J=2.8$ Hz and 9.3
12 Hz), 7.04 (d, 2H, $J=8.5$ Hz), 7.37 (d, 2H, $J=8.5$ Hz), 7.63 (d, 1H, $J=9.5$ Hz). ^{13}C -NMR
13 (125 MHz, $CDCl_3$): δ 16.17 (C6), 20.67 ($-CH_3$, Ac), 20.73 ($-CH_3$, Ac), 20.80 ($-CH_3$, Ac),
14 68.62 (C2), 69.57 (C5), 69.93 (C4), 70.21 (benzyl position), 71.15 (C3), 99.32 (C1),
15 102.32, 107.21, 112.33, 112.37, 114.03, 117.07, 126.40, 129.24, 129.86, 141.57 (q,
16 $J_{C-F}=33.4$ Hz, $-CF_3$), 156.22, 157.22, 159.40, 162.45 ($-C=O$, TFMU), 169.52 ($-C=O$, Ac),
17 170.25 ($-C=O$, Ac), 170.68 ($-C=O$, Ac). ESI-MS (positive mode): $m/z = 631$ [$M + Na$] $^+$,
18 (negative mode): $m/z = 607$ [$M - H$] $^-$. Elemental analysis: Calculated for $C_{29}H_{27}F_3O_{11}$: C,
19 57.24; H, 4.47; F, 9.37; N, 0.00. Found: C, 57.53; H, 4.63; F, 9.33; N, 0.00.

20

21 *Synthesis of substrate 5*: Substrate **2** (62.0 mg; 0.10 mmol) was dissolved in 3 mL
22 CH_3OH , followed by the addition of 28% $NaOCH_3$ in CH_3OH (50 μ L). After stirring at
23 RT for 25 min, the reaction mixture was neutralized by DOWEX 50W-X8 (H^+ form),
24 filtered, and concentrated *in vacuo*. The obtained residue was purified by column
25 chromatography on silica gel (10:1, $CH_2Cl_2:CH_3OH$) to obtain 36.0 mg (73% yield) of
26 substrate **5**. 1H -NMR (500 MHz, $DMSO-d_6$): δ 1.11 (d, 3H, $J_{5-6}=6.0$ Hz, H-6), 3.37-3.53
27 (m, 3H, H-2, H-3, and H-4), 3.74 (qd, 1H, H-5), 4.56 (d, 1H, $-OH$), 4.83 (d, 2H, $J_{1-2}=7.0$
28 Hz, H-1 and $-OH$), 5.16 (d, 1H, $-OH$), 5.17 (s, 2H, benzyl position), 6.84 (s, 1H), 7.01 (d,
29 2H, $J=8.5$ Hz), 7.10 (dd, 1H, $J=2.5$ Hz and 9.0 Hz), 7.23 (d, 1H, $J=2.0$ Hz), 7.40 (d, 2H,

1 $J=8.5$ Hz), 7.61 (d, 1H, $J=7.5$ Hz). ^{13}C -NMR (125 MHz, DMSO- d_6): δ 16.68 (C6),
2 69.88, 69.93 (benzyl position), 70.31 (C5), 71.02, 73.44, 100.48 (C1), 102.62, 106.57,
3 113.37, 114.10, 116.18, 121.81, 125.93, 129.02, 129.75, 139.48 (q, $J_{\text{C-F}}=32.1$ Hz, $-\underline{\text{C}}\text{F}_3$),
4 155.88, 157.44, 158.87, 162.18 ($-\underline{\text{C}}=\text{O}$, TFMU). ESI-MS (positive mode): $m/z = 505$ [M
5 + Na] $^+$, (negative mode): $m/z = 481$ [M - H] $^-$. Elemental analysis: Calculated for
6 $\text{C}_{23}\text{H}_{21}\text{F}_3\text{O}_8$: C, 57.26; H, 4.39; F, 11.81; N, 0.00. Found: C, 57.27; H, 4.36; F, 11.86; N,
7 0.00.

8

9 *Synthesis of substrate 3*: Compound **11** (0.14 g; 0.36 mmol) was dissolved in 30 mL dry
10 THF, followed by the addition of ADDP (0.56 g; 2.18 mmol), TBP (540 μL ; 2.18 mmol),
11 and 2-methyl TokyoGreen (2MeTG; 0.14 g; 0.44 mmol; [3]). After stirring at RT for 60
12 min under N_2 atmosphere, the reaction mixture was concentrated *in vacuo*. The obtained
13 residue was purified by column chromatography on silica gel (1:5, hexane:AcOEt) to
14 obtain 0.22 g (87% yield) of substrate **3**. ^1H -NMR (500 MHz, CDCl_3): δ 1.29 (d, 3H,
15 $J_{5-6}=6.0$ Hz, H-6), 2.02 (s, 3H, $-\underline{\text{C}}\text{H}_3$, Ac), 2.06 (s, 3H, $-\underline{\text{C}}\text{H}_3$, Ac), 2.07 (s, 3H, $-\underline{\text{C}}\text{H}_3$, Ac),
16 2.21 (s, 3H, $-\underline{\text{C}}\text{H}_3$, 2MeTG), 3.98 (qd, 1H, H-5), 5.08 (d, 1H, $J_{1-2}=8.0$ Hz, H-1), 5.10-5.13
17 (m, 3H, H-3 and benzyl position), 5.31 (d, 1H, $J_{3-4}=3.3$ Hz, $J_{4-5}=1.3$ Hz, H-4), 5.48 (dd,
18 1H, $J_{1-2}=8.0$ Hz, $J_{2-3}=10.0$ Hz, H-2), 6.46 (d, 1H, $J=2.0$ Hz), 6.57 (dd, 1H, $J=1.8$ Hz, 9.8
19 Hz), 6.82 (dd, 1H, $J=2.3$ Hz and 8.8 Hz), 6.95 (d, 1H, $J=10.0$ Hz), 6.98 (d, 1H, $J=9.5$
20 Hz), 7.02 (d, 1H, $J=2.5$ Hz), 7.05 (d, 2H, $J=9.0$ Hz), 7.16 (d, 1H, $J=7.5$ Hz), 7.37-7.40
21 (m, 4H), 7.45 (dd, 1H, $J=1.0$ Hz and 7.5 Hz). ^{13}C -NMR (125 MHz, CDCl_3): δ 16.16
22 (C6), 19.65 ($-\underline{\text{C}}\text{H}_3$, 2MeTG), 20.67 ($-\underline{\text{C}}\text{H}_3$, Ac), 20.73 ($-\underline{\text{C}}\text{H}_3$, Ac), 20.79 ($-\underline{\text{C}}\text{H}_3$, Ac),
23 68.61 (C2), 69.57 (C5), 69.90 (C4), 70.28 (benzyl position), 71.13 (C3), 99.27 (C1),
24 101.23, 105.81, 114.00, 114.50, 117.02, 118.33, 126.11, 129.05, 129.29, 129.45, 129.49,
25 129.92, 130.16, 130.57 (x2), 132.45, 136.15, 149.32, 154.52, 157.19, 158.88, 163.20,
26 169.50 ($-\underline{\text{C}}=\text{O}$, Ac), 170.25 ($-\underline{\text{C}}=\text{O}$, Ac), 170.67 ($-\underline{\text{C}}=\text{O}$, Ac), 185.82 ($-\underline{\text{C}}=\text{O}$, 2MeTG).
27 ESI-MS (positive mode): $m/z = 703$ [M + Na] $^+$. Elemental analysis: Calculated for
28 $\text{C}_{39}\text{H}_{36}\text{O}_{11}$: C, 68.81; H, 5.33; N, 0.00. Found: C, 68.83; H, 5.26; N, 0.00.


29

1 *Synthesis of substrate 6*: Substrate **3** (0.11 g; 0.16 mmol) was dissolved in 15 mL
2 CH₃OH, followed by the addition of 28% NaOCH₃ in CH₃OH (15 μL). After stirring at
3 0 °C for 12 h, the reaction mixture was poured into H₂O and extracted three times with
4 AcOEt. The organic layer was then washed with saturated NaCl (aq) and dried over
5 Na₂SO₄. The obtained residue was purified by column chromatography on silica gel (8:1,
6 CH₂Cl₂: CH₃OH) to obtain 63.0 mg (72% yield) of substrate **6**. ¹H-NMR (500 MHz,
7 DMSO-d₆): δ 1.12 (d, 3H, *J*₅₋₆=7.0 Hz, H-6), 2.00 (s, 3H, -CH₃, 2MeTG), 3.36-3.53 (m,
8 3H, H-2, H-3, and H-4), 3.74 (qd, 1H, H-5), 4.52 (d, 1H, -OH), 4.79 (d, 1H, -OH), 4.83
9 (d, 1H, *J*₁₋₂=7.0 Hz, H-1), 5.12 (d, 1H, -OH), 5.19 (s, 2H, benzyl position), 6.24 (d, 1H,
10 *J*=2.0 Hz), 6.43 (dd, 1H, *J*=1.8 Hz and 9.8 Hz), 6.84 (d, 1H, *J*=10.0 Hz), 6.89 (d, 1H,
11 *J*=8.5 Hz), 6.98 (dd, 1H, *J*=2.5 Hz and 8.5 Hz), 7.02 (d, 2H, *J*=8.5 Hz), 7.26 (d, 1H,
12 *J*=7.0 Hz), 7.30 (d, 1H, *J*=2.5 Hz), 7.40 (d, 2H, *J*=8.5 Hz), 7.40-7.52 (m, 3H). ¹³C-NMR
13 (125 MHz, DMSO-d₆): δ 16.61 (C6), 19.12 (-CH₃, 2MeTG), 69.91, 70.04 (benzyl
14 position), 70.28 (C5), 70.98, 73.43, 100.50 (C1), 101.57, 104.78, 113.78, 114.41 (x2),
15 116.19, 117.34, 126.23, 128.98, 129.07, 129.24, 129.56, 129.68, 130.51 (x2), 132.10,
16 135.64, 149.02, 153.98, 157.42, 158.42, 163.29, 184.05 (-C=O, 2MeTG). ESI-MS
17 (positive mode): *m/z* = 555 [M + H]⁺. Elemental analysis: Calculated for C₃₃H₃₀O₈: C,
18 71.47; H, 5.45; N, 0.00. Found: C, 71.46; H, 5.64; N, 0.00.

19

20 **Photochemical characterization of substrates 1 through 6**: Solutions of resorufin and
21 substrates **1** and **4** were prepared at 10 nM in phosphate-buffered saline (PBS) containing
22 2.0×10^{-4} % DMSO. Solutions of TFMU and substrates **2** and **5** were prepared at 100 nM
23 in PBS containing 1.0×10^{-3} % DMSO. Solutions of 2MeTG and substrates **3** and **6** were
24 prepared at 10 nM in PBS containing 1.0×10^{-4} % DMSO. The fluorescence emission
25 spectra of these solutions were recorded at the following appropriate excitation
26 wavelengths: resorufin and substrates **1** and **4**, 571 nm; TFMU and substrates **2** and **5**,
27 385 nm; and 2MeTG and substrates **3** and **6**, 491 nm. The fluorescence emission
28 spectrum of each solution was recorded using a RF-5300PC spectrofluorophotometer
29 (Shimadzu, Kyoto, Japan). The results are summarized in Figures S1 to S3.

1




2

3 **Figure S1.** Overlay of the fluorescence spectra of resorufin and substrates **1** and **4**.

4


5



6

7 **Figure S2.** Overlay of the fluorescence spectra of TFMU and substrates **2** and **5**.

1



2

3 **Figure S3.** Overlay of the fluorescence spectra of 2MeTG and substrates **3** and **6**.

4

5 **Computational analysis**


6 *Calculated of distribution coefficient (clog D) values for substrates 1 through 6:* The
7 clog D values for substrates **1** through **6** were calculated using Structure Design Suite
8 version 12.01 from Advanced Chemistry Development Inc. (Toronto, Canada).

9

10 *Docking study of α -L-fucosidase versus substrates 4 through 6, native substrate, and*
11 *2MeTG α -L-fucopyranoside:* Molecular docking simulations of *Thermotoga maritima*
12 α -L-fucosidase (PDB ID: 2ZXD) to substrates **4** through **6**, native substrate
13 (α -L-fucopyranoside α (1-6) *N*-acetylglucosamine), and 2MeTG α -L-fucopyranoside were
14 carried out using the Molegro Virtual Docker (version 7.0.0; Molexus, Odder, Denmark).
15 In these experiments, we used MolDock scoring function, which is based on a piecewise
16 linear potential, and a re-ranking procedure was applied to the highest ranked poses to
17 increase the docking accuracy. Affinity grid resolution was set to 0.3 Å. Ligand
18 evaluations were based on internal energy of binding, internal H-bond formation, and

1 Sp²-Sp² (trigonal planar electron domain geometry) torsion angles. Candidate cavities
2 for ligand docking were detected by inclusion of pockets with a volume 10–10000 Å³.
3 Among the candidate cavities, the cavity that was bound to a native ligand,
4 6-isopropyl-1-deoxyfuconojirimycin in X-ray structure of *T. maritima* α-L-fucosidase,
5 was selected as an active site for docking. The cavity was measured for cavity volume
6 (108.032 Å³), surface (300.8 Å²), and radius (15.0 Å). The customized search algorithm
7 was set to MolDock Optimizer. Number of runs was 15. Parameter settings were set to
8 2000 iterations, 50 population sizes, 0.50 scaling factor, and 0.90 crossover rate. All
9 dockings were performed at 0.70 Å RMSD threshold.

10



11

12 **Figure S4.** Evaluation of the suitability of the fluorogenic substrates for α-L-fucosidase
13 by docking simulations. Docking models using (A) substrate 4 and (B) substrate 5.

14

15 **General information for cell-based assays:** A human fibrosarcoma cell line (HT-1080;
16 RCB1956), a human cervical cancer cell line (HeLa; RCB0007), and a human
17 neuroblastoma cell line (SK-N-SH; RCB0426) were provided by RIKEN BRC through
18 the National Bio-Resource Project of MEXT, Japan. High-glucose Dulbecco's modified
19 Eagle's medium (D6046) was purchased from Sigma-Aldrich. CELLECT fetal bovine
20 serum (S1820) was purchased from MP Biomedical (Solon, OH, USA). The Lyso-ID
21 Green assay kit (ENZ-51028-K100) was purchased from ENZO Life Sciences (Exeter,
22 UK). DFJ•HCl (FC-007) was purchased from GlycoSyn (Lower Hutt, New Zealand).

1 Chloroquine diphosphate (038-17971), 0.5 w/v% trypsin–5.3 mmol/L EDTA · 4Na
2 solution without phenol red (208-17251), and a 10% formalin solution (064-03843) for
3 tissue fixation were purchased from Wako Pure Chemical Industries, Ltd. (Osaka,
4 Japan). A 35-mm-high μ -Dish for cell imaging (ib81156) was purchased from Ibidi
5 (Gräfelfing, Germany). Fluorescence intensities were recorded using a FluoView
6 FV1000-D confocal laser scanning microscope (Olympus, Tokyo, Japan) equipped with
7 the following filter sets: Alexa Fluor 488 (excitation, 473 nm; dichroic filter, 405/473;
8 and emission, 490–590 nm) for 2MeTG measurements; fluorescein isothiocyanate
9 (excitation, 473 nm; dichroic filter, 405/473; and emission, 490–590 nm) for Lyso-ID
10 Green measurements; Alexa Fluor 568 (excitation, 559 nm; dichroic filter, 405/473/559;
11 emission, 575–675 nm) for resorufin measurements; and 4',6-diamidino-2-phenylindole
12 (excitation, 405 nm; dichroic filter, 405/473; emission, 430–455 nm) for TFMU.

13

14 *Cell-based assays using substrates 1 through 6:* HT-1080, HeLa, and SK-N-SH cells
15 were seeded in μ -Dishes at 4.0×10^4 cells/dish. After incubation at 37 °C for 24 h in 5%
16 CO₂, the medium was replaced with 1 mL of fresh medium. Subsequently, 5 μ L of 2 mM
17 DMSO solutions of substrates **1** through **6** were added to each dish (10 μ M final
18 concentration), followed by incubation at 37 °C for 1 h in 5% CO₂. The medium was
19 removed, and cells were immediately fixed with 10% formalin. Fluorescence signals
20 were recorded using a FluoView FV1000-D microscope (Olympus).

21

22 *Cell-based assays using Lyso-ID Green and substrates 1 and 4:* HT1080 cells were
23 seeded in μ -Dishes at 4.0×10^4 cells/dish. After incubation at 37 °C for 24 h in 5% CO₂,
24 the medium was replaced with 1 mL of fresh medium. Subsequently, 5 μ L of 2 mM
25 DMSO solutions of substrates **1** and **4** was added to the dishes (10 μ M final
26 concentration), followed by incubation at 37 °C for 1 h in 5% CO₂. Next, 200 μ L of dye
27 solution from the Lyso-ID Green assay kit (ENZO Life Sciences) was added, and the
28 cells were incubated at 37 °C in 5% CO₂ for 30 min in the dark. Cells were washed three
29 times with 200 μ L of assay buffer from the kit and immediately fixed with 10% formalin.

1 Fluorescence signals were recorded using a FluoView FV1000-D microscope (Olympus).

2

3 *Chloroquine treatment of cells assayed using Lyso-ID Green and substrate 1:* HT1080
4 cells were seeded in a μ -Dish at 4.0×10^4 cells/dish. After incubation at 37 °C for 24 h in
5 5% CO₂, the medium was replaced with 1 mL of fresh medium. Subsequently, 5 μ L of
6 15 mM chloroquine diphosphate water solution (75 μ M final concentration) was added to
7 the dish, followed by incubation at 37 °C for 2 h in 5% CO₂. The medium was then
8 replaced with 1 mL of fresh medium, followed by addition of 5 μ L of 2 mM DMSO
9 solution of substrate **1** (10 μ M final concentration) to the dish. The cells were incubated
10 at 37 °C for 1 h in 5% CO₂, and the medium was replaced with 1 mL of fresh medium
11 along with 200 μ L of dye solution from the Lyso-ID Green assay kit (ENZO Life
12 Sciences). The cells were then incubated at 37 °C for 30 min in 5% CO₂ in the dark. The
13 cells were washed three times with 200 μ L of assay buffer from the kit and immediately
14 fixed with 10% formalin. Fluorescence signals were recorded using a FluoView
15 FV1000-D microscope (Olympus).

16

17 *Cell-based high-throughput screening for tissue α -L-fucosidase (tFuc) inhibitors:* HeLa
18 cells were seeded in 96-well plates at a density of 1×10^4 cells/well. After incubating the
19 cells at 37 °C for 24 h in 5% CO₂, the medium was replaced with 259 μ L of fresh
20 medium. Subsequently, 1 μ L of 3 mM DMSO solution of substrate **3** (11.5 μ M final
21 concentration) was added to each well, followed by incubation at 37 °C for 6 h to 18 h in
22 5% CO₂. The medium was then removed, and the cells were washed three times with
23 PBS. After washing, 260 μ L of PBS was added to each well, and fluorescence signals
24 from each well were recorded using a microplate reader (Synergy 2; excitation, 485/20
25 nm; and emission, 528/20 nm; BioTek Instruments, Winooski, VT, USA). We defined
26 the optimal assay parameters based on Z' -factor = $1 - (3 \times SD_{\text{substrate 3}} + 3 \times SD_{\text{DMSO}}) /$
27 $(AV_{\text{substrate 3}} - AV_{\text{DMSO}})$, $CV (\%) = (SD_{\text{substrate 3 or DMSO}} / AV_{\text{substrate 3 or DMSO}}) \times 100$, and
28 $\text{Signal / Background ratio} = AV_{\text{substrate 3}} / AV_{\text{DMSO}}$.

29

1 *Cell-based tFuc-inhibition assay:* HeLa cells were seeded in 6-wells plate at 4×10^4
2 cells/dish. After incubating the cells at 37 °C for 24 h in 5% CO₂, the medium was
3 replaced with 2 mL of fresh medium. Subsequently, 10 μL of 50 mM H₂O solution of
4 DFJ•HCl was added to each well (250 μM final concentration), followed incubation at
5 37 °C for 18 h in 5% CO₂. Next, 5 μL of 20 mM DMSO solution of substrate **3** was
6 added to each well (5 μM final concentration), followed by incubation at 37 °C for 1 h in
7 5% CO₂. The medium was then removed and cells were immediately fixed with 10%
8 formalin. Fluorescence signals were recorded using a fluorescence microscope
9 (BIOREVO BZ-9000; Keyence, Osaka, Japan) equipped with filter sets for green
10 fluorescence protein-bandpass (excitation, 470/40 nm; dichroic filter, 495 nm; and
11 emission, 535/50 nm) for 2MeTG measurements. The area of fluorescence (AF) of the
12 observed cells was analyzed using BZ-analyzer (v.2.1; Keyence, Osaka, Japan) and
13 WinROOF 2013 (v.1.2.0; Mitani, Tokyo, Japan). A region including approximately 100–
14 120 cells in the fluorescence image was selected to measure the AF stained by substrate
15 **3**. The average value per cell for both variables was calculated by dividing the total value
16 by the number of semi-manually counted cells. The value of wells was calculated by
17 averaging the values after performing the rejection test with the standard deviation for
18 the five measurement values of each well. The inhibition rate was defined as follows:
19 inhibition rate (%) = (AF DFJ – AF background) / (AF DMSO, negative control – AF
20 background) × 100.


21

22 **General information for *in vitro* assays:** Recombinant human tFuc from *FUCA1* gene
23 (7039-GH) was purchased from R&D Systems (Minneapolis, MN, USA). A
24 flat-bottomed 96 well plate for fluorescent measurement (237105) was purchased from
25 Thermo Fisher Scientific (Waltham, MA, USA). The assays were followed by
26 monitoring the fluorescence intensity change for fluorophore, resorufin, TFMU, and
27 2MeTG, respectively, for 20 min at 120 s intervals using a multi-mode microplate reader
28 (Spark 10M; TECAN, Zürich, Switzerland) at the following conditions: for resorufin
29 measurements (excitation; 570 nm, emission; 590 nm, and gain; 100), for TFMU

1 measurements (excitation; 385 nm, emission; 585 nm, and gain; 125), and for 2MeTG
2 measurements (excitation; 480 nm, emission; 525 nm, and gain; 50).

3
4 *In vitro* α -L-fucosidase assays of recombinant human tFuc. Substrates 4 to 6 were
5 prepared as 50 mM DMSO solutions. These substrate solutions were diluted to 100 μ M
6 in 50 mM sodium acetate buffer including 5 mM MgCl₂ (pH 4.5). Recombinant human
7 tFuc was prepared as 2 ng/ μ L solutions in 50 mM sodium acetate buffer including 5 mM
8 MgCl₂ (pH 4.5). The assays were conducted by adding recombinant human tFuc solution
9 (50 μ L) to each substrate solution (50 μ L), followed by maintenance at 37 °C using a 96
10 well plate and monitoring of the fluorescence intensity change. For substrate blanks, the
11 enzyme solutions were replaced by the same assay buffer.

12 The fluorescence intensity by enzyme hydrolytic action was defined as follows:
13 fluorescence intensity = fluorescence intensity of substrate – fluorescence intensity of
14 substrate blank. Relative rate of hydrolysis was expressed by comparison with the
15 amount of fluorescence intensity that was released from corresponding substrates at 20
16 min, which was taken as 100%.



18
19 **Figure S5.** Hydrolytic activity of recombinant human tFuc for substrates 4 to 6.

1
2 **Gene-expression profiling by DNA microarray:** HeLa cells were seeded in a 25-cm²
3 flask, and after incubation at 37 °C for 5 h in 5% CO₂, the medium was replaced with 4
4 mL of fresh medium. Subsequently, 10 µL of 100 mM H₂O solution of DFJ•HCl (250
5 µM final concentration) and 10 µL of H₂O (negative control) were added to each flask,
6 followed by incubation at 37 °C for 18 h in 5% CO₂. The medium was then removed, and
7 the cells were washed three times with PBS. The cells were then detached using 1 mL of
8 trypsin/EDTA solution and collected in a 1.5-mL tube. Extraction and purification of
9 total RNA from these samples were performed using an RNeasy Mini Kit (74104;
10 Qiagen) according to manufacturer instructions. Concentrations of purified RNA samples
11 were measured using a micro-volume spectrophotometer (Nanodrop 2000; Thermo
12 Fisher Scientific, Waltham, MA, USA). The quality of the RNA samples was evaluated
13 using an RNA 6000 Nano kit (5067-151; Agilent Technologies, Santa Clara, CA, USA)
14 according to manufacturer instructions. Purified, high-quality RNA (1 µg) was converted,
15 amplified, and labeled as cDNA using an Amino Allyl MessageAmp II RNA
16 amplification kit (AM1753; Ambion, Austin TX, USA) and a Cy5 mono-reactive dye
17 pack (PA25001; GE Healthcare, Pittsburgh, PA, USA) according to manufacturer
18 instructions. Obtained cDNAs were hybridized to a 3D-Gene human oligo chip 25k
19 (v.2.1; TRT-XR126; Toray Industries, Tokyo, Japan) according to manufacturer
20 instructions. The chips were scanned (3D-Gene scanner 3000; Toray Industries), and all
21 obtained microarray data were processed using Microsoft Excel (Microsoft, Redmond,
22 WA, USA) and GenMAPP (v.2.1; <http://www.genmapp.org/>).

23 To compare the effects of DFJ treatment relative to negative control cells and
24 identify differentially expressed genes relative to a negative control, normalized data
25 from each array were globally normalized, such that the median of the signal intensity
26 was adjusted to 25. The number of detected genes present at significant levels (global
27 normalization value >100) was determined. Among the detected genes in the DFJ-treated
28 cells, the expression levels of six genes were upregulated (fold change >2.5) and those of
29 other genes were downregulated (fold change <0.45) relative to negative control cells

1 (Tables S1 and S2). Pathway analysis of microarray data to investigate the key molecular
 2 events and functions involved in tFuc inhibition was performed using GenMAPP and
 3 subjected to the following filtering criteria: 1) number of changed (i.e., significantly
 4 differentially expressed) genes in a pathway ≥ 3 ; 2) z-score ≥ 2.0 ; and 3) permutation
 5 p-value ≤ 0.03 . As a result, two identified pathways were upregulated, and two were
 6 downregulated (Table S3).

7
 8 **Table S1.** List of upregulated (fold change >2.5) genes following tFuc inhibition in
 9 HeLa cells.

Gene name	Fold change	\log_2 fold change	Protein name
<i>PGA3</i>	6.51	2.70	Pepsinogen 3, Pepsinogen A, group 1
<i>RAB15</i>	4.71	2.24	Member of RAS oncogene family
<i>ALPI</i>	2.98	1.57	Intestinal alkaline phosphatase
<i>RUNX1</i>	2.71	1.44	Runt-related transcription factor 1
<i>IFIT1</i>	2.67	1.42	Interferon-induced protein with tetratricopeptide repeats 1
<i>ARRB2</i>	2.51	1.33	Arrestin- $\beta 2$

10

11 **Table S2.** List of downregulated (fold change >0.45) genes following tFuc inhibition in
 12 HeLa cells.

Gene name	Fold change	\log_2 fold change	Protein name
<i>JAG1</i>	0.50	-1.01	Replication protein A 70-kDa DNA-binding subunit
<i>COX7B</i>	0.49	-1.03	Cytochrome c oxidase subunit 7B, mitochondrial
<i>CDH2</i>	0.49	-1.04	Cadherin-2
<i>HIF1A</i>	0.49	-1.04	Hypoxia-inducible factor-1 α
<i>DACH2</i>	0.47	-1.11	Dachshund homolog 2
<i>BAT2D1</i>	0.46	-1.11	Protein PRRC2C
<i>CSNK2A1</i>	0.46	-1.13	Casein kinase II subunit- α

13

1

2 **Table S3.** Upregulated and downregulated pathways following tFuc inhibition in HeLa
3 cells.

Pathway name	No. genes		
	showing changes	Z score	P
Small-ligand GPCRs (up)	3	6.13	0.00
Kit-receptor signaling (up)	3	2.60	0.03

Histidine metabolism (down)	3	3.90	0.01
AMP-activated protein kinase signaling (down)	3	2.87	0.03

4

5

6 **References**

- 7 1. Hakamata, W.; Miura, K.; Tanaka, A.; Hirano, T.; Nishio, T. Identification
8 of a novel glycan-processing enzyme with *exo*-acting β -glucosidase activity
9 in the Golgi apparatus using a new platform for the synthesis of
10 fluorescent substrates. *Bioorg. Med. Chem.* **2015**, *23*, 73–79.
- 11 2. Gurale, B. P.; Dhawane, A. N.; Cui, X.; Das, A.; Zhang, X.; Iyer, S. S.
12 Indirect detection of glycosidases using amperometry. *Anal. Chem.* **2016**,
13 *88*, 4248–4253.
- 14 3. Urano, Y.; Kamiya, M.; Kanda, K.; Ueno, T.; Hirose, K.; Nagano, T.
15 Evolution of fluorescein as a platform for finely tunable fluorescence
16 probes. *J. Am. Chem. Soc.* **2005**, *127*, 4888–4894.